Neurology and Neurosurgery

Episodes 65-80 of 352

• 

  RestartResume

  Diagnosing Duchenne Muscular Dystrophy: Recognizing Signs and Reducing Delays

  RestartResume

  Diagnosing Duchenne Muscular Dystrophy: Recognizing Signs and Reducing Delays

  NeuroFrontiers

  Diagnosing Duchenne Muscular Dystrophy: Recognizing Signs and Reducing Delays

  • 

    

    Nancy Kuntz, MD

• 

  RestartResume

  Advances in MS Management: Current and Future Directions

  RestartResume

  Advances in MS Management: Current and Future Directions

  NeuroFrontiers

  Advances in MS Management: Current and Future Directions

• 

  RestartResume

  From Trials to Practice: Evaluating Xanomeline-Trospium Chloride for Schizophrenia 

  RestartResume

  From Trials to Practice: Evaluating Xanomeline-Trospium Chloride for Schizophrenia 

  NeuroFrontiers

  From Trials to Practice: Evaluating Xanomeline-Trospium Chloride for Schizophrenia 

  • 

    

    Ashley Baker, MSN, PMHNP

  • 

    

    Steven Paul, MD

• 

  RestartResume

  Exploring Metabolomics in Multiple Sclerosis

  RestartResume

  Exploring Metabolomics in Multiple Sclerosis

  NeuroFrontiers

  Exploring Metabolomics in Multiple Sclerosis

  • 

    

    Pavan Barghava, MD

• 

  RestartResume

  Safety Outcomes in MS Clinical Trials: Examining Comorbidities and Adverse Events

  RestartResume

  Safety Outcomes in MS Clinical Trials: Examining Comorbidities and Adverse Events

  NeuroFrontiers

  Safety Outcomes in MS Clinical Trials: Examining Comorbidities and Adverse Events

  • 

    

    Amber Salter, PhD

• 

  RestartResume

  Metabolomics in Multiple Sclerosis: Advancing Diagnosis, Prognosis, and Treatment Response

  RestartResume

  Metabolomics in Multiple Sclerosis: Advancing Diagnosis, Prognosis, and Treatment Response

  NeuroFrontiers

  Metabolomics in Multiple Sclerosis: Advancing Diagnosis, Prognosis, and Treatment Response

  • 

    

    Pavan Barghava, MD

• 

  RestartResume

  MS and the Ketogenic Diet: Potential Impacts on Inflammation and Relapse

  RestartResume

  MS and the Ketogenic Diet: Potential Impacts on Inflammation and Relapse

  NeuroFrontiers

  MS and the Ketogenic Diet: Potential Impacts on Inflammation and Relapse

  • 

    

    Michael Kornberg, MD, PhD

• 

  RestartResume

  Managing Multiple Sclerosis: The Impact of Dietary Modifications

  RestartResume

  Managing Multiple Sclerosis: The Impact of Dietary Modifications

  Global Neurology Academy

  Managing Multiple Sclerosis: The Impact of Dietary Modifications

  • 

    

    Charles Turck, PharmD, BCPS, BCCCP

  • 

    

    Anna A. Shah, MD

• 

  RestartResume

  Strategies and Considerations for Managing MS in Pregnant Women

  RestartResume

  Strategies and Considerations for Managing MS in Pregnant Women

  Global Neurology Academy

  Strategies and Considerations for Managing MS in Pregnant Women

  • 

    

    Charles Turck, PharmD, BCPS, BCCCP

  • 

    

    Anna A. Shah, MD

• 

  RestartResume

  Cognitive Impairment in MS: Mitigating Impacts to Optimize Brain Health

  RestartResume

  Cognitive Impairment in MS: Mitigating Impacts to Optimize Brain Health

  NeuroFrontiers

  Cognitive Impairment in MS: Mitigating Impacts to Optimize Brain Health

  • 

    

    Christopher Lock, MD

• 

  RestartResume

  Understanding Prodromal Phases in Demyelinating Diseases: Insights on MS, NMOSD, and MOGAD

  RestartResume

  Understanding Prodromal Phases in Demyelinating Diseases: Insights on MS, NMOSD, and MOGAD

  NeuroFrontiers

  Understanding Prodromal Phases in Demyelinating Diseases: Insights on MS, NMOSD, and MOGAD

  • 

    

    Dalia Rotstein, MD, MPH

• 

  RestartResume

  Emerging Technologies in MS: Neuromodulation and Myelin Regeneration

  RestartResume

  Emerging Technologies in MS: Neuromodulation and Myelin Regeneration

  NeuroFrontiers

  Emerging Technologies in MS: Neuromodulation and Myelin Regeneration

  • 

    

    Cristin Welle, PhD

• 

  RestartResume

  MS and Structural Disconnectivity: Pathophysiology and Emerging Technologies

  RestartResume

  MS and Structural Disconnectivity: Pathophysiology and Emerging Technologies

  NeuroFrontiers

  MS and Structural Disconnectivity: Pathophysiology and Emerging Technologies

  • 

    

    Amy Kuceyeski, PhD

• 

  RestartResume

  Multiple Sclerosis Explained: Understanding Its Epidemiology

  RestartResume

  Multiple Sclerosis Explained: Understanding Its Epidemiology

  NeuroFrontiers

  Multiple Sclerosis Explained: Understanding Its Epidemiology

  • 

    

    Jonathan E. Howard, MD

• 

  RestartResume

  Generalized Myasthenia Gravis Management: Evaluating Long-Term Effects

  RestartResume

  Generalized Myasthenia Gravis Management: Evaluating Long-Term Effects

  NeuroFrontiers

  Generalized Myasthenia Gravis Management: Evaluating Long-Term Effects

  • 

    

    Maxwell H. Levy, MD

• 

  RestartResume

  Uncovering Disparities in Teleneurology Utilization Post-Pandemic

  RestartResume

  Uncovering Disparities in Teleneurology Utilization Post-Pandemic

  Global Neurology Academy

  Uncovering Disparities in Teleneurology Utilization Post-Pandemic

  • 

    

    Marisa McGinley, DO

• Previous
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• …
• 21
• 22
• Next